Regeneron Pharmaceuticals Faces Securities Class Action Lawsuit

🗝️ Key Points

• Summary Regeneron Pharmaceuticals Inc (REGN, Financial), a biotechnology company based in Tarrytown, NY, is facing a securities class action lawsuit filed by Berger Montague PC.
• The lawsuit is on Behalf of investors who purchased Regeneron securities between November 2, 2023, and October 30, 2024.
• The legal action follows allegations by the U.S.

Summary

Regeneron Pharmaceuticals Inc (REGN, Financial), a biotechnology company based in Tarrytown, NY, is facing a securities class action lawsuit filed by Berger Montague PC. The lawsuit is on behalf of investors who purchased Regeneron securities between November 2, 2023, and October 30, 2024. The legal action follows allegations by the U.S. Department of Justice that Regeneron failed to report discounts, leading to inflated Medicare reimbursements. The press release was issued on January 17, 2025.

Positive and Negative Aspects

• Positive: Regeneron is a leading biotechnology company with a diverse product portfolio targeting eye diseases, inflammatory diseases, cancer, and cardiovascular and metabolic diseases.
• Negative: The company is facing legal challenges due to allegations of failing to report discounts, which allegedly inflated drug prices and Medicare reimbursements.
• Negative: Regeneron’s stock price has experienced significant declines following the DOJ’s announcement and disappointing Q3 2024 sales results.

Financial Analyst Perspective

From a financial analyst’s perspective, the ongoing legal issues and the DOJ’s allegations could pose significant risks to Regeneron’s financial stability and investor confidence. The decline in stock price following the announcement of the lawsuit and the missed sales estimates for Eylea indicate potential challenges in maintaining revenue growth. Investors should closely monitor the developments of the lawsuit and any potential financial implications for Regeneron.

Market Research Analyst Perspective

As a market research analyst, the lawsuit against Regeneron highlights the importance of regulatory compliance in the pharmaceutical industry. The allegations of inflated drug prices could impact Regeneron’s market reputation and its relationships with healthcare providers and payers. The company’s ability to address these legal challenges and restore investor confidence will be crucial in maintaining its competitive position in the biotechnology sector.

FAQ

Q: What is the class period for the securities lawsuit against Regeneron?

A: The class period is from November 2, 2023, to October 30, 2024.

Q: What are the allegations against Regeneron?

A: The U.S. Department of Justice alleges that Regeneron failed to report millions of dollars in discounts, leading to inflated Medicare reimbursements.

Q: How did the stock price react to the news?

A: Regeneron’s stock price declined by more than 3% following the DOJ’s announcement and fell by 9% after the Q3 2024 sales report.

Q: What is the deadline for investors to seek lead plaintiff status?

A: Investors have until March 10, 2025, to seek appointment as a lead plaintiff representative.

Read the original press release here.

This article, Generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

MORE IN INSIDE INVESTMENT NEWS

Week in review: Stocks rise, Meta gets real on metaverse, and Salesforce bounces

Published: Saturday, December 6, 2025 · 3:32 PM

Rubrik stock rips 22% higher after blowing out earnings and boosting guidance

Published: Friday, December 5, 2025 · 9:13 PM